Kinnear Pharmaceuticals
Kinnear Pharmaceuticals is a preclinical stage company focused on developing innovative Ceragenin-based treatments for diseases lacking effective solutions. As a subsidiary of N8 Biosciences, it aims to pioneer anti-infective and anti-inflammatory therapies, leveraging proprietary technology based on Dr. Paul B. Savage’s research. The company’s mission is to discover, develop, and bring to market revolutionary product candidates, with a focus on combating resistant infections, biofilms, and inflammatory conditions.
Industries
Nr. of Employees
small (1-50)
Kinnear Pharmaceuticals
3960 Howard Hughes Parkway, Las Vegas, NV, 89169
Products
Inhaled membrane-targeting antimicrobial candidate for cystic fibrosis
Preclinical small-molecule inhaled therapeutic candidate developed to restore antimicrobial activity in cystic fibrosis airways and treat/prevent pulmonary infections caused by Gram-negative and fungal pathogens.
Drug-eluting coated endotracheal tube for prevention of ventilator-associated pneumonia
Medical device project involving a small-molecule drug-eluting coating applied to endotracheal tubes to prevent biofilm formation and reduce ventilator-associated pneumonia in mechanically ventilated patients; subject of ongoing clinical evaluation.
Coated indwelling-device projects (hemodialysis catheters, pacemaker envelopes, pedicle screws)
Development projects for application of antimicrobial drug-eluting coatings to various indwelling devices to reduce hospital-acquired infections, supported by SBIR grant funding.
Inhaled membrane-targeting antimicrobial candidate for cystic fibrosis
Preclinical small-molecule inhaled therapeutic candidate developed to restore antimicrobial activity in cystic fibrosis airways and treat/prevent pulmonary infections caused by Gram-negative and fungal pathogens.
Drug-eluting coated endotracheal tube for prevention of ventilator-associated pneumonia
Medical device project involving a small-molecule drug-eluting coating applied to endotracheal tubes to prevent biofilm formation and reduce ventilator-associated pneumonia in mechanically ventilated patients; subject of ongoing clinical evaluation.
Coated indwelling-device projects (hemodialysis catheters, pacemaker envelopes, pedicle screws)
Development projects for application of antimicrobial drug-eluting coatings to various indwelling devices to reduce hospital-acquired infections, supported by SBIR grant funding.
Services
Preclinical program development including in vitro efficacy testing, biofilm and resistance assessments, proteomics-based mechanism studies, and preparation for regulatory interactions.
Preclinical program development including in vitro efficacy testing, biofilm and resistance assessments, proteomics-based mechanism studies, and preparation for regulatory interactions.
Expertise Areas
- Antimicrobial drug development
- Anti-biofilm therapeutics
- Drug-eluting medical device coatings
- Preclinical development and translational research
Key Technologies
- Membrane-targeting antimicrobial agents
- Antimicrobial peptide mimetics
- Drug-eluting coating technology for medical devices
- Inhaled drug formulation
News & Updates
FDA QiDP designation is a significant milestone for Kinnear Pharmaceuticals, recognizing the importance of CSA-131 in treating Pseudomonas infections in cystic fibrosis patients.
A peer-reviewed publication reports on the efficacy of Ceragenin CSA-131 against Candida auris, a serious global health threat.
Colistin, a last-resort antibiotic, is facing resistance issues as a transferrable gene conferring resistance has been identified.
Research by Professor Jordi Vila shows CSA-131 is effective against colistin-resistant bacterial strains.
FDA QiDP designation is a significant milestone for Kinnear Pharmaceuticals, recognizing the importance of CSA-131 in treating Pseudomonas infections in cystic fibrosis patients.
A peer-reviewed publication reports on the efficacy of Ceragenin CSA-131 against Candida auris, a serious global health threat.
Colistin, a last-resort antibiotic, is facing resistance issues as a transferrable gene conferring resistance has been identified.
Research by Professor Jordi Vila shows CSA-131 is effective against colistin-resistant bacterial strains.